Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APRESOLINE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (oral, as adjunctive therapy),Severe hypertension or hypertensive emergency (parenteral)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.
250 mg orally twice daily
Terminal elimination half-life is 3-7 hours in patients with normal renal function; prolonged to 7-16 hours in renal impairment. Acetylator phenotype affects half-life: in slow acetylators, half-life may be 4-5 hours; in fast acetylators, 1-2 hours, but clinical effect (antihypertensive) lasts longer due to persistent binding to vascular tissue.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Extensively metabolized in the liver via acetylation (N-acetyltransferase, NAT2) and oxidation (CYP450, primarily CYP3A4 and CYP2C19).
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal; 86-90% of an oral dose is excreted in urine as metabolites (N-acetylhydralazine, hydralazine pyruvic acid hydrazone) and unchanged drug (<10% unchanged); biliary/fecal excretion is minimal (<10%).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
87-90% bound to plasma proteins, primarily albumin; binding is reduced in uremia.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.5-1.8 L/kg; distributes widely into total body water, with high affinity for vascular smooth muscle, where it accumulates; Vd is larger in slow acetylators due to higher free drug levels.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral immediate-release: 30-50% in fast acetylators; 50-75% in slow acetylators. Bioavailability is increased when taken with food (peak concentration enhanced 50-70%).
70-90% (oral); 100% (IV).
Cr Cl 10-50 m L/min: administer every 8 hours. Cr Cl <10 m L/min: administer every 8 hours or reduce dose by 50%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Oral: 0.75-3 mg/kg/day in 2-4 divided doses, maximum 7.5 mg/kg/day or 200 mg/day. IV: 0.1-0.2 mg/kg/dose every 4-6 hours as needed.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 10 mg 2-3 times daily; increase gradually to avoid hypotension. Maximum 200 mg/day. Monitor for orthostatic hypotension and reflex tachycardia.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause drug-induced lupus erythematosus, especially in slow acetylators; monitor for symptoms. Use cautiously in patients with coronary artery disease (may cause reflex tachycardia and exacerbate angina). Can cause peripheral neuritis (pyridoxine deficiency), alone with high doses. May cause sodium and water retention, requiring concomitant diuretic therapy.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydralazine or any component of the formulation. Mitral valve rheumatic heart disease. Aortic aneurysm (theoretical contraindication due to increased cardiac output/loading conditions).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Food may increase bioavailability of hydralazine; take with food to reduce peak concentrations and potential side effects. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) if taking MAOIs concurrently. No specific dietary restrictions otherwise.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Second and third trimesters: May cause fetal tachycardia, neonatal hypotension, and ileus; associated with maternal hypotension and potential uteroplacental insufficiency. FDA Pregnancy Category C.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Minimal excretion into breast milk; M/P ratio approximately 1.0. Considered compatible with breastfeeding by the American Academy of Pediatrics; monitor infant for hypotension and feeding difficulties.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No standard dose adjustment recommended; however, increased plasma volume may necessitate higher doses. Monitor response and titrate to effect; avoid severe hypotension to prevent uteroplacental hypoperfusion.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Hydralazine (Apresoline) is a direct-acting vasodilator primarily used for hypertension management, especially in preeclampsia and hypertensive emergencies. It can cause a lupus-like syndrome, especially in slow acetylators; testing for N-acetyltransferase 2 (NAT2) phenotype may be considered. Tachyphylaxis can occur; concomitant beta-blocker and diuretic therapy are often required. Onset of action is 10-20 minutes IV, 20-30 minutes IM. Avoid in patients with coronary artery disease due to reflex tachycardia.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly as this can cause a rapid rise in blood pressure.,May cause dizziness or lightheadedness; avoid driving or operating machinery until you know how this medicine affects you.,Report any unexplained joint pain, fever, chest pain, or rash to your doctor immediately as these may be signs of a serious reaction (drug-induced lupus).,Avoid alcohol consumption as it can increase the blood pressure lowering effects and dizziness.,Do not take over-the-counter cold, sinus, or weight loss products without checking with your doctor, as many contain ingredients that can raise blood pressure.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APRESOLINE vs ALDOCLOR-250, answered by our medical review team.
APRESOLINE is a Antihypertensive that works by Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APRESOLINE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APRESOLINE is: Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APRESOLINE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APRESOLINE is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Second and third trimesters: May cause fetal t. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.